Relationship between Quantitative Monitoring of WT1 Gene and Prognosis in Patients with Acute Leukemia.
10.7534/j.issn.1009-2137.2018.06.009
- Author:
Cui-Yun DOU
1
;
Ji-Lei ZHANG
2
;
Qian HUANG
2
;
Chun-Yan YANG
2
;
Pan-Pan CHENG
2
;
Lei LIU
2
;
Si-Ping LI
2
;
Hao ZHANG
2
Author Information
1. Department of Hematology, The Affiliated Hospital of Jining Medical College, Jining 272029, Shandong Province, China.E-mail: 15866061657@163.com.
2. Department of Hematology, The Affiliated Hospital of Jining Medical College, Jining 272029, Shandong Province, China.
- Publication Type:Journal Article
- MeSH:
Acute Disease;
Gene Expression;
Humans;
Leukemia, Myeloid, Acute;
Neoplasm, Residual;
Prognosis;
WT1 Proteins
- From:
Journal of Experimental Hematology
2018;26(6):1632-1636
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the exprassion of WT1 gene in patients with adult acute myeloid leukemia (AML) and its clinical significance.
METHODS:Sixty-three newly diagnosed patients with acute myeloid leukemia were selected. Quantitative RT-PCR was used to detect the expression of WT1 gene in the 63 AML patients and 20 non-AML controls.
RESULTS:WT1 gene was highly expressed in AML patents and its expression in the low-risk group was significantly lower than that in middle-risk group and high-risk group (P<0.05), and no significant difference of WT1 gene expression between middle-risk and high-risk group was observed. In the patients of middle-risk and high-risk patients, the expression of WT1 gene in the remission group was significantly lower than that in the patients of non-remission after treatment (P<0.05). The non-remission patients after first treatment in middle-risk and high-risk group were treated with second induction therapy. After second induction therapy, the WT1 expression in remission patients was significantly decreased (P<0.05) in comparison with that in patients still in non-remission. There was a negative correlation between WT1 expression and the 2-year overall survival rate in the newly diagnosed middle and high-risk AML patients.
CONCLUSION:The detection of WT1 gene expression can help to divide AML patients into low-/middle-/high-risk groups and to evaluate therapeutic response and clinical prognosis in middle and high-risk AML patients.
